SynAct Pharma AB SYNACT
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
Existing positions may be maintained while new purchases await clearer phase 3 guidance or a completed Brazil agreement.
Strengthened clinical data and confirmed regulatory steps are balanced against low cash and remaining phase 3 risks.
Investors view the new data analysis positively as it de-risks phase 3, despite concerns over insider sales.
HOLD is the call. Positive is the market mood. High risk means a lot can go wrong.
About the company
SynAct Pharma develops resomelagon (AP1189), a melanocortin receptor agonist for resolution of inflammation in rheumatoid arthritis and dengue. The company is in late-stage clinical development and pre-revenue.
Bull case
Post hoc data from ADVANCE validates EXPAND results and paves the way for phase 3 in rheumatoid arthritis.
Bear case
Low cash position and missed primary endpoint in ADVANCE imply continued high execution risk ahead of phase 3.
Sensitivity analysis
| Factor | If it weakens | If it strengthens |
|---|---|---|
| Successful phase 3 initiation in RA | Rejection or demand for additional studies delays development and increases funding needs. | Approved phase 3 design enables partnering deals and higher valuation. |
| Final commercial agreement in Brazil | No binding deal reduces validation and upfront revenue. | Binding agreement brings revenue and broadens indication scope. |
Why this signal
Strengthened clinical data and confirmed regulatory steps are balanced against low cash and remaining phase 3 risks.
Recent news
Post hoc analysis of the phase 2b ADVANCE study confirms prior EXPAND results and reduces placebo-response issues, supporting phase 3 development. FDA discussions on study design are scheduled for Q4 2026. CEO and CSO sold shares to cover Danish tax. USPTO granted a patent for immediate-release resomelagon formulation. WHO highlighted resomelagon as a promising dengue fever candidate.